Miller Andrew Craig 4

4 · Karuna Therapeutics, Inc. · Filed Apr 20, 2023

Form 4

Period: 2023-04-18

Chief Operating Officer

Transactions

Exercise/Conversion
Common Stock
2023-04-18$9.20/sh+30,000$276,000→ 60,900 total
Exercise/Conversion
Common Stock
2023-04-20$9.20/sh+8,500$78,200→ 39,400 total
Sale
Common Stock
2023-04-18$200.16/sh−30,000$6,004,800→ 30,900 total
Sale
Common Stock
2023-04-20$200.13/sh−15,000$3,001,950→ 24,400 total
Exercise/Conversion
Option (right to buy)
2023-04-20−8,500→ 231,992 total
Exercise: $9.20Exp: 2029-03-20→ Common Stock (8,500 underlying)
Exercise/Conversion
Option (right to buy)
2023-04-18−30,000→ 240,492 total
Exercise: $9.20Exp: 2029-03-20→ Common Stock (30,000 underlying)

Footnotes (3)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2022.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.04 to $200.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
[F3]This option vested and became exercisable in thirty equal monthly installments beginning on April 21, 2019.

Documents

1 file